<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>External request</strong></td>
<td>Submission request from Myriad Genetic Laboratories to recommend consideration of a multi-syndrome gene panel for patients meeting clinical testing criteria for a hereditary colon cancer syndrome.</td>
<td>YES NO ABSTAIN ABSENT</td>
</tr>
<tr>
<td></td>
<td>• Based on consensus, the panel added a new section to the NCCN Guidelines for Genetics/Familial High-Risk Assessment: Colorectal titled, “Multi-gene testing”. In addition, the option of “multi-gene testing” was added to:</td>
<td>12 0 0 14</td>
</tr>
<tr>
<td></td>
<td>o Meets clinical testing criteria for Lynch syndrome (LS) with no known LS mutation for both testing strategies of tumor available and no tumor available or insufficient tumor.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Routine tumor testing criteria for LS for both testing strategies of tumor available and no tumor available or insufficient tumor but clinical testing criteria are met.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>o For testing strategy of no known APC or biallelic MUTYH mutation(s)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>See Submission for references.</td>
<td></td>
</tr>
</tbody>
</table>